Table 2.
Efficacy of the anti-SARS-Co-2 vaccination to prevent COVID-19, hospitalizations, and death
| Outcome and immunization status | Total cohort |
Patients with COVID-19 |
Vaccine efficacy |
||
|---|---|---|---|---|---|
| Number of person-ds | No. of persons | Incidence rate (number of events/1000 person-ds) | Age-adjusted and sex-adjusted analysis | Analysis adjusted for all variables | |
| COVID-19 diagnosis | |||||
| Unvaccinated | 221,873 | 193 | 0.870 | - | - |
| (0.755–1.001) | |||||
| Complete vaccination | 2,075,679 | 1069 | 0.515 | 18.4% | 18.1% |
| (0.485–0.546) | (12.2%–24.1%) | (11.8%–23.8%) | |||
| Hospitalizations | |||||
| Unvaccinated | 236,976 | 86 | 0.363 | - | - |
| (0.294–0.448) | |||||
| Complete vaccination | 2,187,193 | 227 | 0.104 | 42.8% | 42.8% |
| (0.091–0.118) | (35.7%–49.1%) | (35.6%–49.1%) | |||
| Deaths | |||||
| Unvaccinated | 240,169 | 67 | 0.279 | - | - |
| (0.219–0.354) | |||||
| Complete vaccination | 2,223,586 | 56 | 0.025 | 65.8% | 66.0% |
| (0.019–0.032) | (60.4%–70.5%) | (60.6%–70.7%) | |||
The incidence rate (number of events per 1000 person-days) from infection, hospitalization, and death from COVID-19 in unvaccinated patients (n =1196) and in patients with complete vaccination (n = 10,215) is shown.
Patients with complete vaccination were considered as those who had greater than or equal to 14 days after receipt of the second dose. Efficacy of vaccination (estimated as 1 minus the hazard ratio adjusted for covariates, expressed as percentage) to reduce risk of infection, hospitalization, or death with its 95% CI are presented.